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Abstract
Purpose—Radiation therapy increases stroke risk in pediatric cancer patients, but risk of stroke
recurrence in this population remains unknown. In a retrospective cohort study, we assessed rates
and predictors of first and recurrent stroke in patients treated with cranial irradiation (CRT) and/or
cervical irradiation ≤ 18 years of age.
Methods—We performed chart abstraction (n=383) and phone interviews (n=104) to measure
first and recurrent stroke in 383 patients who received CRT and/or cervical radiation at a single
institution between1980–2009. Stroke was defined as a physician diagnosis and symptoms
consistent with stroke. Incidence of first-stroke was number of first-strokes per person-years of
observation after radiation. We used survival analysis techniques to determine cumulative
incidence of first and recurrent stroke.
Results—Among 325 subjects with sufficient follow-up data, we identified 19 first-strokes (13
ischemic, 4 hemorrhagic, 2 unknown sub-type) occurring at a median age of 24 years
(Interquartile range (IQR) 17–33 years) in patients treated with CRT. Imaging was reviewed when
available (n=13) and the stroke was confirmed in 12. Overall rate of first-stroke was 625 (95% CI
378–977) per 100,000 person-years. The cumulative incidence of first stroke was 2% (95% CI
0.01–5.3%) at 5 years and 4% (95% C.I. 2.0–8.4%) at 10 years post irradiation. With each 100cGy
increase in the radiation dose, the stroke hazard increased by 5% (Hazard ratio = 1.05; 95% CI
1.01–1.09; p=0.02). We identified 6 recurrent strokes; 5 had available imaging that confirmed the
stroke. Median time to recurrence was 15 months (IQR 6 months–3.2 years) after first-stroke. The
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cumulative incidence of recurrent stroke was 38% (95% CI 17–69%) at 5 years and 59% (95% CI
27–92%) at 10 years post first-stroke.
Conclusion—CRT puts childhood cancer survivors at high risk of both first and recurrent
stroke. Stroke prevention strategies for these survivors are needed.
Introduction
Cranial radiation therapy (CRT) has been associated with significant long-term sequelae
including increased risk of stroke; however, no information is available on the risk of
recurrent stroke after first stroke in survivors of childhood cancer (1–3). Analyses from the
Childhood Cancer Survivor Study (CCSS), a retrospective cohort study with longitudinal
follow-up of 14,358 childhood cancer survivors and 4,023 sibling controls, suggest that the
risk of stroke is significantly elevated among survivors of pediatric central nervous system
(CNS) tumors and acute lymphoblastic leukemia (ALL). CRT was the strongest stroke
predictor and increased stroke risk in a dose dependent manner; not surprisingly, CNS tumor
survivors were found to carry a very high stroke risk compared to controls (2).
The underlying mechanism through which radiation therapy increases stroke risk is not well
understood. Moyamoya, a specific form of cerebral vasculopathy characterized by non-
atherosclerotic progressive stenosis of the terminal internal carotid arteries, is more
prevalent in children with ALL and CNS tumors who undergo CRT than those children who
did not require CRT (4, 5). Head and neck cancer studies have shown that radiation therapy
causes accelerated atherosclerosis even within one year from treatment (6, 7). A recent
analysis of the CCSS cohort showed that the risk of late-occurring stroke (≥ five years from
initial cancer diagnosis) is CRT dose-dependent and continues to increase as these survivors
age. In addition, atherosclerotic risk factors such as hypertension (HTN) contributed to this
elevated stroke risk. Age at time of CRT did not influence stroke risk, although others have
reported an increase in silent lacunar infarcts the younger the child at time of radiation
therapy (8, 9).
The underlying cellular process of this delayed radiation injury is thought to be related to
chronic oxidative stress (10). Cells exposed to radiation have been shown to increase the
production of reactive oxygen species causing damage to proteins and lipids. Activation of
these pathways can lead to chronic inflammation, increasing the risk of atherosclerotic
plaque development and rupture. These data suggest that treatment with radiation therapy
may increase the stroke risk by at least two mechanisms: (1) a non-atherosclerotic radiation-
induced cerebral vasculopathy referred to as moyamoya in its most severe form; and (2) by
accelerated atherosclerosis through chronic inflammation.
A large cohort study of children with stroke showed that those with underlying
vasculopathies have an extraordinarily high risk of recurrent stroke: 66% at five years (11).
Because the mechanism of stroke in pediatric cancer survivors who received CRT is likely a
radiation-induced vasculopathy, we hypothesized that risk of recurrent stroke is similarly
high in pediatric cancer survivors with first-stroke. We identified first and recurrent strokes
in a retrospective cohort of children with cancer who were treated with cranial or neck
irradiation ≤ 18 years of age at a single institution. In order to inform primary and secondary
stroke prevention strategies in this high-risk population, we sought to define the incidence
and predictors of both first and recurrent stroke after radiation therapy.
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Methods
Setting
This is a retrospective cohort study of patients treated at a single institution from 1980 to
2009 with cranial or cervical irradiation therapy for an underlying malignancy ≤ age of 18
years. Patients were identified through the institutional Cancer Registry. The institutional
review board approved this study.
Patients
Eligibility criteria for enrollment in this study included (1) age ≤18 years at the time of
radiation therapy, (2) radiation therapy to the brain and/or cervical area between 1980
and2009 (3) survival ≥ one year from radiation therapy, and (4) signed consent. The
institutional review board granted a waiver of informed consent to perform chart review on
patients lost to follow-up.
Data Collection
Eligible patients (n=406) were contacted by mail to invite participation in the study; 23
declined and were excluded from the study. Chart review was performed on the remaining
383 patients; of these, 104 (or surrogates where necessary) consented/assented to a
telephone interview. Interviews were carried out with either the patient (if alive and ≥18
years of age at the time of the study; n=71) or the legal guardian of patients currently <18
years (n=20) or deceased (n=13).
During the interview, participants were asked specific questions about baseline
demographics (age, sex, race), the cancer diagnosis and treatment, and complications of
treatment or the cancer itself with a specific focus on stroke, stroke symptoms, potential
treatment for stroke, and stroke recurrence. Chart review included abstraction of basic
demographic information such as age, race and sex. Cancer diagnosis was based on
pathology report, and date of surgery was confirmed by operative report. We recorded
whether or not patients received chemotherapy as part of their treatment. Clinical records
were reviewed for evidence of stroke after radiation therapy and stroke recurrence after first
stroke.
Stroke outcomes were identified by either chart review or interview, and included ischemic
and hemorrhagic stroke. Stroke based on chart review was defined as both physician
documentation of a stroke diagnosis and clinical signs or symptoms consistent with an
ischemic or hemorrhagic stroke (e.g., acute onset focal neurological deficits, headache,
altered mental status, and/or seizure). Stroke based on interview was similarly defined as a
history of a health care provider communicating the diagnosis of stroke to the participant
and clinical symptoms consistent with stroke. Strokes within seven days after brain surgery
were excluded.
When stroke outcomes were identified, we attempted to obtain all relevant brain imaging,
including, with patient/guardian consent, studies performed at outside hospitals. Two
pediatric neurologists (HF, SM) independently reviewed the imaging to confirm findings
consistent with stroke. A radiation oncologist (DHK) reviewed radiation records and
location of strokes to assess if strokes occurred in the territories of arteries within the
radiation field.
Statistical Analysis
The overall annual incidence of first-stroke was calculated as the total number of first-
strokes divided by the sum of person-years of observation from date of radiation therapy to
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date of first-stroke, death or last follow up. Last follow-up was defined as the date of the
interview or date of last documented medical encounter (admission or clinic visit),
whichever came last. We used survival analysis techniques to determine the cumulative
incidence of first-stroke; the time period at risk began with the date of the first radiation
therapy and subjects who did not have an event were censored at the time of death or date of
last follow up. Cox proportional hazards models were used to assess risk factors for first-
stroke within this cohort; hazard ratios (HR) and associated confidence intervals (CI) were
calculated as a measure of relative risk. We examined as predictors in univariate analyses:
age at time of radiation therapy and diagnosis, radiation therapy dose, treatment with
chemotherapy, race, and gender. The multivariable model was based on univariate
screening, and included those predictors that were significantly associated with risk of first
stroke (p<0.05). Among the subcohort of patients with first-stroke, we used survival analysis
techniques to determine the cumulative incidence of recurrent stroke; the time period at risk
began with the date of the first stroke, and subjects who did not have a recurrence were
censored at death or last follow-up.
Results
Of the 383 patients subjected to chart review, 325 had sufficient longitudinal clinical data
and constituted the final study cohort. There were no differences in baseline characteristics
between the 58 subjects excluded due to loss to follow-up and the 325 with follow-up data
(data not shown). The final cohort had a median follow-up time of 7.3 years (Interquartile
range (IQR) 2.4–15.0 years). The majority of patients were alive (n=227; 70%), and only 5
patients in our cohort had a history of neurofibromatosis type 1 (NF1). Patients who were
available for interview (in addition to chart review) had similar characteristics compared to
patients who could not be interviewed in terms of gender (p=0.21), race (p=0.43), age at
diagnosis (p=0.63) and history of NF1 (p=0.63) (supplemental Table 1). However, patients
who were not interviewed were significantly younger at the last follow-up than patients who
were interviewed (p=0.01) and as expected were more likely to have died (p<0.0001)
(supplemental Table 1).
First Stroke after Radiation Therapy
In this cohort, we identified a total of 19 first strokes after CRT (Table 1): 6 from chart
review (5 out of 6 confirmed by imaging), 9 from interviews (3 out of 9 confirmed by
imaging), and 4 from both sources (all 4 confirmed by imaging). Out of 13 cases with
available imaging, 12 had imaging findings consistent with stroke. The other had extensive
brain calcifications that precluded definitive confirmation of a stroke; however, we decided
to include this stroke outcome in the analysis based on the clinical diagnosis. The median
age at first-stroke was 24 years (IQR 17–33 years). Median time to develop a first stroke
after CRT was 12 years (IQR 5–18 years). A total of 11 patients received treatment for their
stroke (Table 1). Thirteen strokes were ischemic, 4 were hemorrhagic, and the stroke type
was unknown in two.
The overall rate of first-stroke was 625 per 100,000 person-years (95% CI 378–977 per
100,000). It was 429/100,000 person-years for patients identified by chart review only and
198/100,000 for patients identified based by interview only. As shown in Figure 1 and Table
2, the cumulative incidence of first stroke after radiation therapy increased over time elapsed
since radiation therapy.
Risk Factors of First Stroke after Cranial Radiation Therapy
Table 3 lists results of the univariate analysis. Each 100cGy increase in CRT dose increased
the risk of stroke by 5% (HR 10.5; 95% CI 1.01–1.09; p=0.02). Males had an increased
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stroke risk compared to females (HR 3.2 95% CI 1.0– 9.6; p= 0.04). For every additional
year of age at time of radiation therapy, risk of stroke increased by 12% (95% CI 1.0–1.2
p=0.01) (Table 3). In the multivariable analysis, dose of radiation retained borderline
significance, even when adjusted for age at radiation and gender (HR 1.04, 95% CI 1.00,
1.09, p=0.07).
Recurrent Stroke in Children treated with Radiation Therapy
Of the 19 subjects who had a first stroke, 6 had recurrent strokes (5 identified by interview
and one by chart review) (Table 1). One out of these 6 had more than one recurrent event.
We confirmed 5 out of 6 recurrent strokes on imaging. For one patient we were unable to
attain the images. The earliest recurrent stroke occurred 6 months after first stroke, with the
last recorded recurrence at 9 years. The median time between first stroke and recurrence was
15 months (IQR 6 months–3.2 years) (see Figure 2); stroke recurrence occurred at a median
age of 27 years (IQR 26–34). The cumulative incidence of recurrent stroke was 20% (95%
CI 7–50%) at 1 year after first-stroke, 38% (95% CI 17–69%) at 5 years and 59% (95% CI
27–92%) at 10 years. Of the 6 patients with recurrent strokes, 4 had been treated with aspirin
after their first stroke. One subject carried a diagnosis of NF1. Imaging reports commenting
on vascular findings were available in 2 out 6 patients; one patient had evidence of
moyamoya and one patient had evidence of internal carotid calcifications, a finding seen in
atherosclerosis.
Discussion
In this retrospective cohort study of cancer patients treated with CRT and/or cervical
irradiation under 18 years of age, we identified 19 first strokes after CRT and identified a
high 5-year cumulative recurrence rate of 38%. To our knowledge this is the first report that
specifically investigated the risk of stroke recurrence in this high-risk population. We found
that with each 100 cGy increase in radiation dose the risk of first stroke increases by 5%.
This is in concordance with other reports showing a dose dependent effect of radiation on
stroke risk (2, 5). As expected, the majority of patients with stroke carried a diagnosis of a
brain tumor that most likely reflects the use of higher radiation dosages in this population.
None of the patients with just cervical irradiation were found to have a stroke. The overall
rate of first stroke in this study was 625 per 100,000 person-years after radiation therapy.
Prior studies have estimated stroke rates of 2.3 per 100,000 in children and between 7–15
per 100,000 in young adults defined as < 45 years of age (12, 13). A recent retrospective
analysis from Children’s Hospital in Philadelphia reports a similar stroke rate of 548 per
100,000 in patients receiving CRT (14). Radiation to the circle of Willis has been shown to
be an important predictor of cerebrovascular disease (1, 14). Of the 19 patients with first
strokes in our cohort, 12 patients received radiation to the circle of Willis as defined by
Campen, et al (14). However, we were unable to assess radiation to the Circle of Willis as a
stroke predictor in this current study because incomplete radiation records precluded
measurement in a significant number of patients.
As suggested by results of the CCSS, which described self-reported first-strokes, childhood
cancer survivors continue to be at significant stroke risk even decades after initial treatment
as they enter adulthood. We similarly found that the cumulative incidence of first stroke
increases more than 8-fold from 2% at 5 years to 17% at 20 years after radiation therapy;
these strokes are occurring in adolescence to young adulthood when the stroke risk in the
general population is still very low. Enhanced awareness of these risks by healthcare
providers, caregivers, and patients alike would help ensure that there are no delays in stroke
diagnosis.
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Surprisingly, we found that each additional year of age at time of radiation increased stroke
risk by 12%. Similar results were found by Campen, et al. (14), who reported a 13%
increase in the risk of cerebrovascular events [including transient ischemic attacks (TIA) and
stroke] with each additional year at age of cancer diagnosis. These results contrast with
reports by others indicating that age less than 5 years at time of radiation therapy is a strong
predictor of lacunar infarcts, thought to be secondary to small vessel vasculopathy (9).
Results from CCSS, however, suggest that age at time of diagnosis as a surrogate for age at
radiation therapy does not influence the risk of stroke (2). If and how age at time of radiation
therapy influences the risk of stroke requires additional studies.
This is the first study to specifically assess the risk of recurrent stroke in this high-risk
population. We identified 6 recurrent strokes: of these, 2 had evidence of vasculopathies
based on imaging review. In a large population-based pediatric cohort study, the overall
cumulative rate of recurrent ischemic stroke was 19% at 5 years post stroke, with the highest
risk in children who had evidence of vasculopathies: a 5-year cumulative recurrence rate of
66% (11). In our current study we also found a high 5-year cumulative recurrence rate of
38%. Children with evidence of cerebral vasculopathies or history of first ischemic stroke
are often started on anti-platelet agents. Out of 6 patients with recurrent stroke 4 were
treated with an anti-platelet agent after first stroke. It is conceivable that the underlying
mechanism of radiation-induced vasculopathies is a chronic inflammatory process and
therefore other treatment strategies such as anti-inflammatory agents may prove more
efficacious. Additional investigations are required to better characterize the group of
pediatric cancer survivors at highest risk of recurrent strokes in order to develop strategies
for secondary stroke prevention.
Our study is limited by the biases and limitations of retrospective analyses as well as recall
bias of patients and/or their proxies that participated in interviews. However, we were able
to confirm on imaging the majority of stroke outcomes. Furthermore, 4 patients had
confirmed stroke outcomes based on both chart reviews and interviews. All patients whose
outcomes could only be measured by interview and not chart review had only brief follow-
up. As a tertiary care center patients are often referred only for radiation therapy and are
then followed locally. Additional factors such as presence of atherosclerotic risk factors (e.g.
hypertension) may play a critical role in this population as suggested by a recent analysis
from the CCSS (8); we were unable to capture these reliably by chart review or by
interviews and therefore were unable to include such factors in the current analysis. A
further limitation was that the median follow up time for the cohort was 7.3 years (IQR 2.4 –
15 years) but median time to first stroke was 12 years (IQR 5–18 years). With longer
duration of follow up we would likely have identified more first strokes, as well as more
recurrent strokes; hence, our stroke rates may be under estimates. Further, to estimate the
rate of recurrent stroke we used survival technique analysis and censored patients either at
time of death or last follow up. It is conceivable that patients who contribute more person-
years of observation to follow up are different from the patients who died and are less ill.
That could also potentially lead to under estimates of recurrent strokes.
In conclusion, pediatric cancer patients treated with CRT, have an elevated stroke risk and a
high risk of recurrent stroke after first stroke. To date, we have limited information on the
timing and incidence of radiation induced vasculopathies since vascular imaging is not
routinely obtained. Prospective studies are urgently needed to better characterize the
vascular effects of radiation therapy and to assess if additional factors such as modifiable
atherosclerotic risk factors are contributing to stroke risk. We have initiated a prospective
cohort study using MR-angiography of the head and neck in children who are receiving
radiation therapy; results will inform the incidence of radiation-induced vasculopathies,
strokes, and stroke recurrence in this high-risk group of patients.
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Summary
No data are available on the risk of recurrent stroke in pediatric cancer survivors treated
with radiation therapy to the brain and/or neck. We retrospectively evaluated the risk of
stroke in 325 children with cancer treated with brain and/or neck radiation therapy. The
overall rate of first-stroke was 625 per 100,000 person-years. The 5-year cumulative
stroke recurrence rate was high at 38% (95% CI 17–69%). Stroke prevention strategies
are needed for this high-risk population.
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Figure 1.
Cumulative Incidence of First Stroke after Cranial Radiation Therapy in Pediatric Cancer
Patients
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Figure 2.
(A) Cumulative Incidence of First Stroke after First Stroke in Pediatric Cancer Patients. (B)
Depicted is the time from first to recurrent stroke for each patient with a histor of stroke
recurrence (n=6)
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